Compounding, Compounding Pharmacies and Diabetes

STAT+: FDA confirms shortage of weight loss drug tirzepatide is over, gives compounders a grace period

STAT

DECEMBER 19, 2024

The agency said it would give these compounders a grace period of 60 to 90 days before enforcing rules that would put a halt to their work, in an effort to avoid disruption for patients.

Compounding

STAT+: Novo Nordisk’s Ozempic and Wegovy, long in shortage, are now listed as available by FDA

STAT

OCTOBER 30, 2024

Semaglutide, the scientific name for Novo’s GLP-1 diabetes drug Ozempic and obesity drug Wegovy, has been on the shortage list for over two years, with different doses being listed in shortage at various times. Continue to STAT+ to read the full story…

STAT+: Compounders lose legal battle with FDA over removal of Eli Lilly’s weight loss drug from a shortage list

STAT

MAY 7, 2025

Food and Drug Administration over a decision last year to remove two Eli Lilly drugs — the Zepbound weight loss medicine and the Mounjaro diabetes treatment — from a shortages list kept by the agency. The move means that patients will no longer have access to cheaper versions from compounding pharmacies.

Compounding

STAT+: The end of compounded GLP-1 copies leaves many patients in a ‘lose-lose’ position

STAT

APRIL 29, 2025

The explosion of compounded GLP-1 offerings over the past two years is coming to an end, and many patients are left with no good options. Businesses are changing prescriptions, mixing in additives, or encouraging stockpiling of existing compounded products. Some have disappeared altogether.

Compounding

STAT+: Court ruling opens door to FDA action against Ozempic compounders

STAT

APRIL 25, 2025

Novo Nordisk has notched a major legal win against compounding pharmacies that make copies of its diabetes and obesity drug semaglutide, sold under the brand names Ozempic and Wegovy. Compounding pharmacies are legally allowed to make versions of branded treatments if the drugs are deemed to be in shortage by the FDA.

Compounding

STAT+: Pharmalittle: We’re reading about Novo and GLP-1 compounding, Paxlovid and long Covid, and more

STAT

JANUARY 6, 2025

Food and Drug Administration seeking to block compounding pharmacies in the U.S. The latest attempt focuses on liraglutide, an older, once-daily injectable product sold as Victoza and Xultophy for diabetes and Saxenda for obesity. … Novo Nordisk filed another citizen’s petition with the U.S.

Compounding

Compounding Compounding Pharmacies Diabetes Communication

STAT+: Novo asks FDA to bar compounders from making Ozempic copies

STAT

OCTOBER 22, 2024

Novo Nordisk has asked the Food and Drug Administration to bar compounding pharmacies from making copies of its blockbuster weight loss drug semaglutide, arguing that the medication is too complex for the pharmacies to safely make.

Compounding

Compounding Compounding Pharmacies Documentation Diabetes

STAT+: Lilly sues compounders, wellness centers and spas over unapproved versions of Mounjaro

STAT

SEPTEMBER 20, 2023

As the gold rush over weight-loss drugs accelerates, Eli Lilly filed lawsuits against several compounding pharmacies, spas and wellness centers around the U.S. for selling unapproved versions of its Mounjaro diabetes drug, which is frequently used for combating obesity.

Compounding

STAT+: Compounding group sues FDA for removing Lilly’s obesity drug from its shortages list

STAT

OCTOBER 8, 2024

A trade group representing large compounding pharmacies has sued the U.S. Food and Drug Administration for a “reckless and arbitrary” decision to remove a widely prescribed Eli Lilly drug for combating diabetes and obesity from an official shortages list. Continue to STAT+ to read the full story…

Compounding

Compounding Compounding Pharmacies Diabetes Drug Pricing

STAT+: In stark reversal, FDA to reconsider removal of Eli Lilly weight loss drug from shortage list

STAT

OCTOBER 11, 2024

The Food and Drug Administration on Friday said it would reconsider its decision to remove Eli Lilly’s tirzepatide, sold as Mounjaro for diabetes and Zepbound for obesity, from its shortage list, and, for the time being, would not pursue regulatory action against certain compounding pharmacies making copies of the drugs.

STAT+: Eli Lilly weight loss drug shortage underscores deeper issues with FDA oversight

STAT

OCTOBER 25, 2024

Earlier this month, the FDA declared an end to the shortage of Lilly’s tirzepatide, sold as Mounjaro for diabetes and Zepbound for obesity, after almost two years. By law, that should have prohibited compound pharmacies from making copies of the drug, as they’re allowed to do so only when the treatment is on the shortage list.

STAT+: Pharmalittle: We’re reading about Zepbound price and dose changes, compounders suing FDA, and more

STAT

FEBRUARY 25, 2025

… Eli Lilly will offer more doses of its obesity drug Zepbound in vials and lower the prices of the doses it already sells, as the company seeks to draw patients away from cheap, compounded copies of weight loss medications , STAT reports. Pharmacy compounders sued the U.S.

Compounding

Compounding Compounding Pharmacies Diabetes Communication

STAT+: Pharmalittle: We’re reading about Novo targeting compounded obesity drugs, an Amgen ‘at risk’ launch, and more

STAT

OCTOBER 23, 2024

Food and Drug Administration to bar compounding pharmacies from making copies of its blockbuster weight loss drug semaglutide, arguing that the medication is too complex for the pharmacies to safely make , STAT reports. … Novo Nordisk has asked the U.S. appeals court ruling in its favor , Reuters writes.

Compounding

Compounding Compounding Pharmacies Biosimilars Documentation

STAT+: Pharmalittle: Lilly sues spas and compounders over ‘unapproved’ Mounjaro; nasal-spray EpiPen alternative suffers setback

STAT

SEPTEMBER 20, 2023

… As the gold rush over weight-loss drugs accelerates, Eli Lilly filed lawsuits against several compounding pharmacies, spas and wellness centers around the U.S. for selling unapproved versions of its Mounjaro diabetes drug, which is frequently used for combating obesity, STAT writes.

Compounding

STAT+: Eli Lilly weight loss drug shortage underscores deeper issues with FDA oversight

STAT

OCTOBER 25, 2024

Earlier this month, the FDA declared an end to the shortage of Lilly’s tirzepatide, sold as Mounjaro for diabetes and Zepbound for obesity, after almost two years. By law, that should have prohibited compound pharmacies from making copies of the drug, as they’re allowed to do so only when the treatment is on the shortage list.

Don’t Ignore Erectile Dysfunction

Compounding Pharmacy of America

DECEMBER 6, 2024

While many men experience occasional difficulties with sexual performance, persistent ED can be an early warning sign of serious underlying health issues such as cardiovascular disease, diabetes, or hormonal imbalances.

STAT+: Pharmalittle: We’re reading about a Zepbound-Wegovy faceoff, compounders slamming Novo, and more

STAT

DECEMBER 4, 2024

It mirrors results seen in the companies’ diabetes drugs, which use the same active ingredients. A trade group for compounding pharmacies slammed an attempt by Novo Nordisk to convince the U.S. That, in turn, could help the company gain market share against Novo.

Compounding

Compounding Compounding Pharmacies Diabetes Documentation

Diabetes advocacy group discourages use of compounded GLP-1 drugs

BioPharma Dive

DECEMBER 2, 2024

The ADA recommended doctors avoid prescribing unapproved, off-brand versions of drugs like Wegovy, wading into a dispute that has gripped the FDA and compounding pharmacies over the past few months.

Compounding

FDA rethinking block on compounding of Lilly's obesity drug

pharmaphorum

OCTOBER 14, 2024

Faced with lawsuit, FDA rethinks block on compounding pharmacies making Eli Lilly's diabetes and obesity drug tirzepatide

Compounding

STAT+: Pharmalittle: We’re reading about the FDA listing Novo drugs as ‘available,’ pharma layoffs, and more

STAT

OCTOBER 31, 2024

… All doses of Novo Nordisk’s blockbuster diabetes and obesity treatments are listed as available on the U.S. With all doses now listed as available, the FDA may soon pull it off the list, depending on its conversations with Novo about whether the company can sufficiently meet demand going forward.

Compounding Pharmacies Compounding Diabetes Packaging

Novo joins Lilly in asking FDA for ban on GLP-1 compounding

pharmaphorum

OCTOBER 23, 2024

Novo Nordisk has asked the FDA to stop compounding pharmacies making cheaper versions of its semaglutide-based therapies for obesity and diabetes, saying the drug is too complex to be made safely by these manufacturers.

Compounding

STAT+: Pharmalittle: More than 9 in 10 pharmacy techs report drug shortages; Yale and VA strike deal over ketamine patent royalties

STAT

SEPTEMBER 22, 2023

The techs who were queried identified chemotherapies; ADHD medicines; three drugs for weight loss and diabetes — Mounjaro, Ozempic, and Wegovy — and local anesthetics such as lidocaine as the top drugs experiencing shortages. And 72% said shortages very significantly or significantly impact their workflow.

Department of Veterans Affairs

Department of Veterans Affairs Pharmacy Technician Compounding Pharmacies Compounding

ASBM Statement on FDA Announcing End of 2-Year GLP-1 Shortage

Safe Biologics

MARCH 5, 2025

On February 22nd, the US Food and Drug Administration (FDA) announced the resulution of a years-long shortage of semaglutide, the key ingredient in popular GLP-1 weight loss and diabetes medications Ozempic amd Wegovy. drug manufacturers would be on the low end for risk and pharmacy compounders would be on the high end.

Supplements and Compounding Diabetic Medications

Compounding Pharmacy of America

FEBRUARY 23, 2023

Many people need to address diabetes. So, how well does compounding diabetic medication address symptoms and one’s lifestyle? The post Supplements and Compounding Diabetic Medications appeared first on The Compounding Pharmacy of America.

Compounding

Compounding Diabetes Compounding Pharmacies

Diabetes and Compounded Medications: A Personalized Approach to Chronic Care

Compounding Pharmacy of America

MAY 27, 2025

Discover how compounded medications offer custom support for diabetes, neuropathy, and hormone balance. The post Diabetes and Compounded Medications: A Personalized Approach to Chronic Care appeared first on Compounding Pharmacy of America. Tailored care for better results.

Compounding

Compounding Diabetes Compounding Pharmacies

STAT+: Pharmalittle: We’re reading about FDA oversight of shortages, AstraZeneca threats, and more

STAT

OCTOBER 25, 2024

Earlier this month, the FDA declared an end to the shortage of Lilly’s tirzepatide, sold as Mounjaro for diabetes and Zepbound for obesity, after almost two years. By law, that should have prohibited compounding pharmacies from making copies of the drug, as they are allowed to do so only when the treatment is on the shortage list.

Compounding

Compounding Compounding Pharmacies Diabetes Drug Development

How To Choose A GLP-1 Compounding Pharmacy | Tips And Benefits

Welltopia Pharmacy

OCTOBER 17, 2024

A GLP-1 compounding pharmacy offers patients a customized, often more affordable alternative. Glucagon-like peptide-1 (GLP-1) receptor agonists have become essential in managing type 2 diabetes and aiding in weight loss.

The Role of GLP-1 Therapies in Type 2 Diabetes Prevention and Treatment

Compounding Pharmacy of America

MARCH 29, 2024

An exploration of how proper diet, exercise, and a regiment of supplements combined with GLP-1 therapies can prevent and treat type 2 diabetes. The post The Role of GLP-1 Therapies in Type 2 Diabetes Prevention and Treatment appeared first on The Compounding Pharmacy of America.

Diabetes

Diabetes Compounding Pharmacies Compounding

From A to Zinc: How Vitamins Help Manage Diabetes

Compounding Pharmacy of America

JULY 11, 2023

For those who are diabetic, there are vitamins, supplements, and compounding medications that can help you manage your condition. The post From A to Zinc: How Vitamins Help Manage Diabetes appeared first on The Compounding Pharmacy of America.

Diabetes

Diabetes Compounding Pharmacies Compounding

Diabetes Drug Shortages and Fake Ozempic

National Association of Boards of Pharmacy

DECEMBER 13, 2023

Injectable diabetes medications including semaglutide, namely Wegovy and Ozempic, have been in shortage since 2022 , limiting patient access to the drug across the nation. Simultaneously, compounding pharmacies have been overwhelmed with the production of semaglutide injections that are compounded copies of Ozempic and Wegovy.

Diabetes

Diabetes Compounding Pharmacies Compounding Online Pharmacies

What Health Problems Are Related to Poor Oral Hygiene?

Compounding Pharmacy of America

AUGUST 24, 2022

When health professionals look in your mouth, your oral health can show symptoms of serious conditions like heart disease, diabetes and […]. appeared first on The Compounding Pharmacy of America. The post What Health Problems Are Related to Poor Oral Hygiene?

STAT+: Pharmalittle: We’re reading about compounded Wegovy, pharmacies suing GoodRx, and more

STAT

NOVEMBER 6, 2024

… Novo Nordisk disclosed that it is aware of 10 deaths and 100 hospitalizations resulting from people taking compounded copies of its weight loss and diabetes drugs , Reuters writes. Given all the U.S. could inject themselves with a product that was not regulated, approved, or inspected.

Compounding

Compounding Compounding Pharmacies Diabetes Hospitals

The Science Behind Saving Dessert for Last

Fusion Pharmacy

AUGUST 29, 2023

Hot Weight Loss Medications/Products That Have Recently Hit the Market Semaglutide, the active ingredient in brand-name drugs such as Ozempic, Wegovy, and Rybelsus, which were designed for the management of type 2 diabetes, have also been shown to be effective for weight loss.

STAT+: Pharmalittle: We’re reading about compounders suing the FDA, Biogen turning to telehealth, and more

STAT

OCTOBER 8, 2024

… A trade group representing large compounding pharmacies has sued the U.S. Food and Drug Administration for a “reckless and arbitrary” decision to remove a widely prescribed Eli Lilly drug for combating diabetes and obesity from an official shortages list , STAT tells us.

Compounding

Compounding Compounding Pharmacies Vaccines Immunization

USP announces new Advanced Technologies Laboratory to accelerate and scale pharmaceutical manufacturing innovations

Pharmacy Times

JUNE 4, 2025

USP labs provide unparalleled expertise in developing quality and process standards, establishing and validating analytical methods, characterizing impurities, and synthesizing organic compounds. The Advanced Technologies Lab is the latest of USP’s investments in advanced manufacturing technologies.

Pharmaceutical Manufacturing

Pharmaceutical Manufacturing Pharmacy Technician Compounding Pharmacies Compounding

New Online Competency Modules Standardize CPA Pharmacist Training at Academic Medical Center

Pharmacy Times

JUNE 9, 2025

For example, CPAs are especially impactful in managing chronic conditions such as diabetes, heart failure, and rheumatoid arthritis, where pharmacist intervention has been shown to improve outcomes and reduce hospitalizations. Creating disease-specific competency assessments also ensures alignment with evolving standards of care.

Pharmacy Technician Compounding Pharmacies Diabetes Hospitals

Study Reveals Gaps in GINA Guideline Adherence for Asthma Treatment

Pharmacy Times

JUNE 9, 2025

News All News FDA Updates Press Releases Media All Videos Digital Detail Independent Corner Insights Interviews MEDcast Medical World News Microsites Peer Exchange Perfect Consult Podcasts Practice Pearls Sponsored Webcast Student Voices Webinars/Webcasts Conferences Conference Coverage Conference Listing Publications Pharmacy Times Pharmacy Practice (..)

Pharmacy Technician Compounding Pharmacies Hospitals Pharmacy Management

FDA Approves First, Only Single-Pill Triple Combination for Treatment of Hypertension

Pharmacy Times

JUNE 9, 2025

News All News FDA Updates Press Releases Media All Videos Digital Detail Independent Corner Insights Interviews MEDcast Medical World News Microsites Peer Exchange Perfect Consult Podcasts Practice Pearls Sponsored Webcast Student Voices Webinars/Webcasts Conferences Conference Coverage Conference Listing Publications Pharmacy Times Pharmacy Practice (..)

Pharmacy Technician Compounding Pharmacies Pharmacy Management Diabetes

McKesson Corporation Completes Acquisition of Core Ventures

Pharmacy Times

JUNE 3, 2025

billion, enhancing community-based oncology care and clinical development. billion, enhancing community-based oncology care and clinical development.

Pharmacy Technician Specialty Pharmacies Compounding Pharmacies Pharmacy Management

Specialty Pharmacist Integration in Neurology Clinics: A Model for Enhanced Patient Care

Pharmacy Times

JUNE 8, 2025

News All News FDA Updates Press Releases Media All Videos Digital Detail Independent Corner Insights Interviews MEDcast Medical World News Microsites Peer Exchange Perfect Consult Podcasts Practice Pearls Sponsored Webcast Student Voices Webinars/Webcasts Conferences Conference Coverage Conference Listing Publications Pharmacy Times Pharmacy Practice (..)

Pharmacy Technician Specialty Pharmacies Communication Immunization

Rilonacept in Recurrent Pericarditis: Mechanism of Action, Patient Management, and Clinical Considerations

Pharmacy Times

JUNE 6, 2025

News All News FDA Updates Press Releases Media All Videos Digital Detail Independent Corner Insights Interviews MEDcast Medical World News Microsites Peer Exchange Perfect Consult Podcasts Practice Pearls Sponsored Webcast Student Voices Webinars/Webcasts Conferences Conference Coverage Conference Listing Publications Pharmacy Times Pharmacy Practice (..)

Pharmacy Technician Specialty Pharmacies Diabetes Compounding Pharmacies

Study Finds VPS72 Is Overactive in Patients With Hepatocellular Carcinoma

Pharmacy Times

JUNE 6, 2025

1,2 MASH, formerly known as nonalcoholic steatohepatitis, is a severe form of metabolic dysfunction-associated steatotic liver disease (MASLD) that often accompanies various metabolic diseases (eg, obesity and diabetes). Major risk factors of HCC are metabolic dysfunction-associated steatohepatitis (MASH) and viral hepatitis.

Pharmacy Technician Compounding Pharmacies Diabetes Pharmacy Management

ASCO 2025: Vepdegestrant Shows Superiority to Fulvestrant in ER+/HER2- Advanced Breast Cancer

Pharmacy Times

JUNE 9, 2025

months versus 2.1 months versus 2.1